Slingshot members are tracking this event:
Gilead (GILD) Announces Top-Line Results From Two Phase 3 Studies Evaluating Momelotinib for Patients With Myelofibrosis
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
Slingshot Insights Explained
Nov 16, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Momelotinib, Myelofibrosis, Simplify-2, Simplify-1, Thrombocytopenia, Diarrhea, Headache, Dizzine, Momelotinib